71.05
-0.42 (-0.59%)
| Previous Close | 71.47 |
| Open | 71.47 |
| Volume | 127,581 |
| Avg. Volume (3M) | 1,794,205 |
| Market Cap | 2,391,545,088 |
| Price / Earnings (TTM) | 66.40 |
| Price / Earnings (Forward) | 77.52 |
| Price / Sales | 10.69 |
| Price / Book | 18.15 |
| 52 Weeks Range | |
| Earnings Date | 28 Apr 2025 - 2 May 2025 |
| Profit Margin | 10.03% |
| Operating Margin (TTM) | 19.12% |
| Diluted EPS (TTM) | 1.41 |
| Quarterly Revenue Growth (YOY) | 48.20% |
| Quarterly Earnings Growth (YOY) | 110.60% |
| Total Debt/Equity (MRQ) | 194.67% |
| Current Ratio (MRQ) | 9.10 |
| Operating Cash Flow (TTM) | 49.38 M |
| Levered Free Cash Flow (TTM) | -84.81 M |
| Return on Assets (TTM) | 4.21% |
| Return on Equity (TTM) | 22.99% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Mixed |
| Medical Devices (Global) | Bearish | Mixed | |
| Stock | TransMedics Group, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 4.0 |
| Average | 1.70 |
|
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 3.03% |
| % Held by Institutions | 121.56% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 145.00 (Piper Sandler, 104.10%) | Buy |
| Median | 137.50 (93.54%) | |
| Low | 130.00 (Oppenheimer, 82.98%) | Buy |
| Average | 137.50 (93.54%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 120.66 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 04 Jun 2025 | 145.00 (104.10%) | Buy | 129.81 |
| 09 May 2025 | 125.00 (75.94%) | Buy | 111.50 | |
| Oppenheimer | 09 May 2025 | 130.00 (82.98%) | Buy | 111.50 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| RANGANATH ANIL P. | - | 139.40 | -686 | -95,628 |
| Aggregate Net Quantity | -686 | |||
| Aggregate Net Value ($) | -95,628 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 139.40 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| RANGANATH ANIL P. | Officer | 09 Jun 2025 | Sell (-) | 686 | 139.40 | 95,628 |
| Date | Type | Details |
|---|---|---|
| 27 May 2025 | Announcement | TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
| 20 May 2025 | Announcement | TransMedics to Present at Upcoming June Investor Conferences |
| 08 May 2025 | Announcement | TransMedics Reports First Quarter 2025 Financial Results |
| 24 Apr 2025 | Announcement | TransMedics to Report First Quarter 2025 Financial Results on May 8, 2025 |
| 02 Apr 2025 | Announcement | TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
| 24 Mar 2025 | Announcement | SHAREHOLDER DEADLINE: TransMedics Group (TMDX) Investors Are Reminded of Deadline in Securities Action |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |